Implantable cardioverter

• US 4,403,614 A
• Filed: 02/27/1981
• Issued: 09/13/1983
• Est. Priority Date: 07/19/1979
• Status: Expired due to Term

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Engle, William R., Rockland, Ronald H., Spear, Joseph F. Jr., Moore, E. Neil Jr.
• Primary Examiner(s): Kamm, William E.
• Application Number:
  US06/239,007
• Time in Patent Office: 928 Days
• Field of Search: 128/419 D, 128/705
• US Class Current: 607/5
• CPC Class Codes: A61N 1/385 Devices for inducing an abnormal cardiac function, e.g. fibrillation
• CPC Class Codes: A61N 1/3956 Implantable devices for applying electric shocks to the heart, e.g. for cardioversion

Abstract

A body implantable ventricular cardioverting system. Circuitry is provided which detects the onset of a malignant ventricular tachyarrhythmia and provides a cardioverting signal in response thereto. The cardioverting signal has an energy level that is high relative to the pacing threshhold but below that necessary for defibrillation. In this manner, a ventricular tachyarrhythmia can be cardioverted before the onset of fibrillation and at a lower energy than required for defibrillation. Dependent on such factors as patient threshholds, the tissue/electrode interface and the electrode system employed, the energy level of the cardioverting signal is from 5 millijoules to 15 joules. The system can be configured such that increasingly malignant tachyarrhythmias result in higher energy cardioverting signals, including signals capable of defibrillation. Successful cardioversion with a signal having an energy level lower than necessary for defibrillation reduces the physical damage to the heart as well as the trauma to and discomfort of the patient.

Claims

1. A body implantable ventricular cardioverter which comprises:

means for detecting the onset of a malignant ventricular tachyarrhythmia;

means responsive to the detecting means for providing a cardioverting signal, said cardioverting signal having an energy level that is high relative to a typical pacing threshold of 50 microjoules and below 45 joules that is typically necessary for defibrillation.

2. The cardioverter of claim 1 wherein said detecting means comprises means responsive to the first malignant ventricular tachyarrhythmic event.

3. The cardioverter of claim 1 wherein said cardioverting signal providing means comprises means for storing the energy for said cardioverting signal.

4. The cardioverter of claim 3 wherein said cardioverting signal providing means comprises means for charging said energy storing means in response to the onset of a malignant ventricular tachyarrhythmia.

5. The cardioverter of claim 4 wherein said detecting means comprises means responsive to the first malignant ventricular tachyarrhythmic event.

6. The cardioverter of claim 3 wherein said cardioverting signal providing means comprises means for maintaining said energy storing means in a charged state.

7. The cardioverter of claim 6 wherein said detecting means comprises means responsive to the first malignant ventricular tachyarrhythmic event.

8. The cardioverter of claim 1 wherein said cardioverting signal providing means repetitively provides cardioverting signals during said tachyarrhythmia.

9. A body implantable cardioverter which comprises:

means for detecting the onset of a malignant ventricular tachyarrhythmia;

means responsive to the detecting means for providing a cardioverting signal having an energy level from 5 millijoules to 15 joules; and

output means for delivering said cardioverting signal.

10. The cardioverter of claim 9 wherein said output means comprises endocardial electrode means, the energy level of said cardioverting signal being from 10 joules to 15 joules.

11. The cardioverter of claim 10 wherein said endocardial electrode means each have a surface area of approximately 500 mm².

12. The cardioverter of claim 9 wherein said output means comprises epicardial electrode means, the energy level of said cardioverting signal being from 5 millijoules to 250 millijoules.

13. The cardioverter of claim 12 wherein said epicardial electrode means comprise circular means each having a contact surface area of approximately 500 mm².

14. The cardioverter of claim 9 wherein said detecting means comprises means responsive to the first malignant ventricular tachyarryhmic event.

15. The cardioverter of claim 9 wherein said cardioverting signal providing means repetitively provides cardioverting signals during said tachyarrhythmia.

16. The method of cardioverting malignant ventricular tachyarrhythmias which comprises:

detecting the onset of a malignant ventricular tachyarrhythmia; and

delivering, in response thereto, a cardioverting signal having an energy level that is high relative to a typical pacing threshold of 50 microjoules and below 45 joules that is typically necessary for defibrillation.

17. The method of claim 16 wherein the step of delivery comprises the step of delivering a cardioverting signal having an energy level from 5 millijoules to 15 joules.

18. The method of claim 17 wherein the step of delivering comprises the step of repetitively delivering said cardioverting signals during said tachyarrhythmia.